Dianthus Therapeutics, Inc. /DE/ Operating Lease Cost
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Operating Lease Cost of $98.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for the quarter ending 2026-06-30 was $98.00K, a 1.01% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for the quarter ending 2026-03-31 was $99.00K, a 19.51% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for the quarter ending 2025-12-31 was $98.00K, a 12.50% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for the quarter ending 2025-09-30 was $76.00K, a 26.92% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for fiscal 2025 was $396.00K, a 6.16% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for fiscal 2024 was $422.00K, a 15.30% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for fiscal 2023 was $366.00K, a 84.85% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ operating lease, cost for fiscal 2022 was $198.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $98.00K 10-Q · filed 2026-08-04 | $197.00K 10-Q · filed 2026-08-04 | $295.00K derived: sum of 3 quarters · filed 2026-08-04 | $371.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $99.00K 10-Q · filed 2026-05-05 | $197.00K derived: sum of 2 quarters · filed 2026-05-05 | $273.00K derived: sum of 3 quarters · filed 2026-05-05 | $372.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $174.00K derived: sum of 2 quarters · filed 2026-03-09 | $273.00K derived: sum of 3 quarters · filed 2026-08-04 | $396.00K 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $76.00K 10-Q · filed 2025-11-05 | $175.00K derived: sum of 2 quarters · filed 2026-08-04 | $298.00K 10-Q · filed 2025-11-05 | $410.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $99.00K 10-Q · filed 2026-08-04 | $222.00K 10-Q · filed 2026-08-04 | $334.00K derived: sum of 3 quarters · filed 2026-08-04 | $438.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $123.00K 10-Q · filed 2026-05-05 | $235.00K derived: sum of 2 quarters · filed 2026-05-05 | $339.00K derived: sum of 3 quarters · filed 2026-05-05 | $442.00K derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $216.00K derived: sum of 2 quarters · filed 2026-03-09 | $319.00K derived: sum of 3 quarters · filed 2026-03-09 | $422.00K 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $104.00K 10-Q · filed 2025-11-05 | $207.00K derived: sum of 2 quarters · filed 2025-11-05 | $310.00K 10-Q · filed 2025-11-05 | $413.00K derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $103.00K 10-Q · filed 2025-08-07 | $206.00K 10-Q · filed 2025-08-07 | $309.00K derived: sum of 3 quarters · filed 2025-08-07 | $397.00K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $103.00K 10-Q · filed 2025-05-12 | $206.00K derived: sum of 2 quarters · filed 2025-05-12 | $294.00K derived: sum of 3 quarters · filed 2025-05-12 | $382.00K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $191.00K derived: sum of 2 quarters · filed 2025-03-11 | $279.00K derived: sum of 3 quarters · filed 2025-03-11 | $366.00K 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $88.00K 10-Q · filed 2024-11-07 | $176.00K derived: sum of 2 quarters · filed 2024-11-07 | $263.00K 10-Q · filed 2024-11-07 | $351.00K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $88.00K 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2023-08-03 | $175.00K 10-Q · filed 2024-08-08 | $1.60M 10-Q · filed 2023-08-03 | $263.00K derived: sum of 3 quarters · filed 2024-08-08 | $329.00K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $87.00K 10-Q · filed 2024-05-09 | $1.60M 10-Q · filed 2023-05-15 | $175.00K derived: sum of 2 quarters · filed 2024-05-09 | $241.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.84M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $154.00K derived: sum of 2 quarters · filed 2024-03-21 | $1.75M derived: sum of 3 quarters · filed 2024-03-21 | $198.00K 10-K · filed 2024-03-21 | $6.41M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $66.00K 10-Q · filed 2023-11-09 | $1.60M 10-Q · filed 2022-11-03 | $1.67M derived: sum of 2 quarters · filed 2023-11-09 | $110.00K 10-Q · filed 2023-11-09 | $4.80M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $1.60M 10-Q · filed 2023-08-03 | $3.20M 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | $1.60M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |